Does the media favor CLDX or OPK?

In the previous week, OPKO Health had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 15 mentions for OPKO Health and 9 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.15 beat OPKO Health's score of 0.43 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer OPK or BCRX?

In the previous week, OPKO Health had 7 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 15 mentions for OPKO Health and 8 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat OPKO Health's score of 0.43 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ZBIO or OPK?

OPKO Health has higher revenue and earnings than Zenas BioPharma. OPKO Health is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zenas BioPharma $10M 197.85 -$377.74M -$8.47 N/A OPKO Health $606.90M 1.63 -$225.68M -$0.09 N/A

Does the media prefer ZBIO or OPK?

In the previous week, OPKO Health had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for OPKO Health and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat OPKO Health's score of 0.43 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, INVA or OPK?

Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.74 $271.17M $6.01 3.47 OPKO Health $606.90M 1.63 -$225.68M -$0.09 N/A

Is INVA or OPK more profitable?

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -12.40%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% OPKO Health -12.40% -5.88% -3.83%

Does the media refer more to INVA or OPK?

In the previous week, OPKO Health had 6 more articles in the media than Innoviva. MarketBeat recorded 15 mentions for OPKO Health and 9 mentions for Innoviva. Innoviva's average media sentiment score of 0.96 beat OPKO Health's score of 0.43 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, OPK or MNKD?

MannKind has lower revenue, but higher earnings than OPKO Health. MannKind is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OPKO Health $606.90M 1.63 -$225.68M -$0.09 N/A MannKind $348.97M 3.49 $5.86M -$0.07 N/A

Is OPK or MNKD more profitable?

MannKind has a net margin of -6.63% compared to OPKO Health's net margin of -12.40%. OPKO Health's return on equity of -5.88% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets OPKO Health -12.40% -5.88% -3.83% MannKind -6.63% -11.21% -3.92%

Does the media prefer OPK or MNKD?

In the previous week, OPKO Health had 3 more articles in the media than MannKind. MarketBeat recorded 15 mentions for OPKO Health and 12 mentions for MannKind. MannKind's average media sentiment score of 0.88 beat OPKO Health's score of 0.43 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral MannKind 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OPKO Health (OPK) Competitors

$1.31 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.33 +0.02 (+1.53%)

As of 04:35 PM Eastern

Compare

OPK vs. CLDX, BCRX, ZBIO, INVA, and MNKD

Should you buy OPKO Health stock or one of its competitors? MarketBeat compares OPKO Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OPKO Health include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and MannKind (MNKD).

How does OPKO Health compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and OPKO Health (NASDAQ:OPK) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Celldex Therapeutics currently has a consensus price target of $54.62, indicating a potential upside of 39.31%. OPKO Health has a consensus price target of $1.55, indicating a potential upside of 16.98%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OPKO Health has higher revenue and earnings than Celldex Therapeutics. OPKO Health is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,998.18	-$258.76M	-$4.26	N/A
OPKO Health	$606.90M	1.63	-$225.68M	-$0.09	N/A

In the previous week, OPKO Health had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 15 mentions for OPKO Health and 9 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.15 beat OPKO Health's score of 0.43 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

64.6% of OPKO Health shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Celldex Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Celldex Therapeutics has a net margin of 0.00% compared to OPKO Health's net margin of -12.40%. OPKO Health's return on equity of -5.88% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
OPKO Health	-12.40%	-5.88%	-3.83%

Summary

OPKO Health beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

How does OPKO Health compare to BioCryst Pharmaceuticals?

OPKO Health (NASDAQ:OPK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, OPKO Health had 7 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 15 mentions for OPKO Health and 8 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat OPKO Health's score of 0.43 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.63	-$225.68M	-$0.09	N/A
BioCryst Pharmaceuticals	$874.84M	2.59	$263.86M	-$1.78	N/A

OPKO Health currently has a consensus price target of $1.55, indicating a potential upside of 16.98%. BioCryst Pharmaceuticals has a consensus price target of $20.80, indicating a potential upside of 133.05%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

OPKO Health has a net margin of -12.40% compared to BioCryst Pharmaceuticals' net margin of -51.71%. OPKO Health's return on equity of -5.88% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-12.40%	-5.88%	-3.83%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BioCryst Pharmaceuticals beats OPKO Health on 10 of the 16 factors compared between the two stocks.

How does OPKO Health compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Zenas BioPharma has a beta of -1.03, suggesting that its share price is 203% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

In the previous week, OPKO Health had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for OPKO Health and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat OPKO Health's score of 0.43 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zenas BioPharma presently has a consensus price target of $44.29, indicating a potential upside of 41.31%. OPKO Health has a consensus price target of $1.55, indicating a potential upside of 16.98%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Zenas BioPharma is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OPKO Health has higher revenue and earnings than Zenas BioPharma. OPKO Health is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	197.85	-$377.74M	-$8.47	N/A
OPKO Health	$606.90M	1.63	-$225.68M	-$0.09	N/A

Zenas BioPharma has a net margin of 0.00% compared to OPKO Health's net margin of -12.40%. OPKO Health's return on equity of -5.88% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
OPKO Health	-12.40%	-5.88%	-3.83%

64.6% of OPKO Health shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

OPKO Health beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does OPKO Health compare to Innoviva?

Innoviva (NASDAQ:INVA) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Innoviva presently has a consensus target price of $36.20, indicating a potential upside of 73.56%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 16.98%. Given Innoviva's stronger consensus rating and higher possible upside, equities research analysts plainly believe Innoviva is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 44.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.74	$271.17M	$6.01	3.47
OPKO Health	$606.90M	1.63	-$225.68M	-$0.09	N/A

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -12.40%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
OPKO Health	-12.40%	-5.88%	-3.83%

In the previous week, OPKO Health had 6 more articles in the media than Innoviva. MarketBeat recorded 15 mentions for OPKO Health and 9 mentions for Innoviva. Innoviva's average media sentiment score of 0.96 beat OPKO Health's score of 0.43 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Innoviva has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Summary

Innoviva beats OPKO Health on 12 of the 16 factors compared between the two stocks.

How does OPKO Health compare to MannKind?

OPKO Health (NASDAQ:OPK) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

MannKind has a net margin of -6.63% compared to OPKO Health's net margin of -12.40%. OPKO Health's return on equity of -5.88% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-12.40%	-5.88%	-3.83%
MannKind	-6.63%	-11.21%	-3.92%

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

OPKO Health has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, MannKind has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

OPKO Health currently has a consensus target price of $1.55, indicating a potential upside of 16.98%. MannKind has a consensus target price of $9.34, indicating a potential upside of 136.85%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has lower revenue, but higher earnings than OPKO Health. MannKind is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.63	-$225.68M	-$0.09	N/A
MannKind	$348.97M	3.49	$5.86M	-$0.07	N/A

In the previous week, OPKO Health had 3 more articles in the media than MannKind. MarketBeat recorded 15 mentions for OPKO Health and 12 mentions for MannKind. MannKind's average media sentiment score of 0.88 beat OPKO Health's score of 0.43 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
MannKind	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OPKO Health and MannKind tied by winning 8 of the 16 factors compared between the two stocks.

Get OPKO Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPK vs. The Competition

Export

Metric	OPKO Health	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$988.89M	$9.87B	$6.79B	$13.03B
Dividend Yield	N/A	2.54%	2.60%	10.03%
P/E Ratio	-14.72	25.68	279.71	25.52
Price / Sales	1.63	4.84	649.11	116.03
Price / Cash	N/A	26.44	28.64	34.82
Price / Book	0.79	5.20	11.16	6.36
Net Income	-$225.68M	$312.25M	$3.48B	$347.60M
7 Day Performance	-20.30%	-0.87%	2.55%	3.18%
1 Month Performance	-13.49%	-0.89%	-2.76%	-2.03%
1 Year Performance	3.54%	24.91%	64.39%	21.31%

OPKO Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPK OPKO Health	1.6176 of 5 stars	$1.31 flat	$1.55 +18.3%	+10.1%	$977.69M	$606.90M	N/A	1,373
CLDX Celldex Therapeutics	2.9965 of 5 stars	$35.65 +1.0%	$52.77 +48.0%	+69.9%	$2.77B	$1.54M	N/A	150	Upcoming Earnings
BCRX BioCryst Pharmaceuticals	3.8193 of 5 stars	$9.58 +2.6%	$20.80 +117.1%	+10.8%	$2.37B	$874.84M	N/A	530	Positive News Upcoming Earnings
ZBIO Zenas BioPharma	3.4804 of 5 stars	$32.82 +8.0%	$44.29 +34.9%	+102.0%	$1.92B	$10M	N/A	N/A	News Coverage Positive News Upcoming Earnings
INVA Innoviva	3.2116 of 5 stars	$21.30 -0.7%	$36.20 +70.0%	+11.5%	$1.58B	$411.33M	3.54	100	Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPK) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, ZBIO, INVA, and MNKD

How does OPKO Health compare to Celldex Therapeutics?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Summary

How does OPKO Health compare to Zenas BioPharma?

Summary

How does OPKO Health compare to Innoviva?

Summary

How does OPKO Health compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, ZBIO, INVA, and MNKD

How does OPKO Health compare to Celldex Therapeutics?

Do analysts recommend CLDX or OPK?

Which has higher valuation & earnings, CLDX or OPK?

Does the media favor CLDX or OPK?

Do insiders & institutionals believe in CLDX or OPK?

Which has more risk & volatility, CLDX or OPK?

Is CLDX or OPK more profitable?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Does the media prefer OPK or BCRX?

Which has more risk & volatility, OPK or BCRX?

Which has stronger valuation and earnings, OPK or BCRX?

Do analysts rate OPK or BCRX?

Is OPK or BCRX more profitable?

Do institutionals & insiders believe in OPK or BCRX?

Summary

How does OPKO Health compare to Zenas BioPharma?

Which has more volatility and risk, ZBIO or OPK?

Does the media prefer ZBIO or OPK?

Do analysts recommend ZBIO or OPK?

Which has preferable valuation and earnings, ZBIO or OPK?

Is ZBIO or OPK more profitable?

Do institutionals and insiders believe in ZBIO or OPK?

Summary

How does OPKO Health compare to Innoviva?

Do analysts recommend INVA or OPK?

Do institutionals & insiders believe in INVA or OPK?

Which has stronger valuation & earnings, INVA or OPK?

Is INVA or OPK more profitable?

Does the media refer more to INVA or OPK?

Which has more risk and volatility, INVA or OPK?

Summary

How does OPKO Health compare to MannKind?

Is OPK or MNKD more profitable?

Do institutionals and insiders believe in OPK or MNKD?

Which has more risk and volatility, OPK or MNKD?

Do analysts prefer OPK or MNKD?

Which has stronger earnings and valuation, OPK or MNKD?

Does the media prefer OPK or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools